Women’s Heart Health Belongs in the Benefits Conversation

  • 3 Min read

  • May 20, 2026

Susan Thomas

Susan Thomas

Chief Commercial Officer, LucyRx
Best Practices
Women's Heart Health

Cardiovascular disease is the leading cause of death in women.

As a nurse, I cannot look at that fact and separate it from how we talk about menopause, midlife health, and benefits.

For many women, midlife is when health starts to change in ways that are easy to miss or easy to explain away. Sleep changes. Weight changes. Blood pressure changes. Cholesterol changes. Energy changes. New symptoms show up, and too often women are told it is “just menopause” or “just aging.”

But midlife is not just a symptoms conversation.

It is also a heart health conversation.

During perimenopause and menopause, cardiometabolic risk rises. Changes in body composition, insulin resistance, inflammation, cholesterol, and blood pressure can begin before a diabetes diagnosis lands. They build quietly. They do not always arrive with a clear label.

That is why this matters for employers.

Benefit conversations still tend to treat menopause, heart health, weight, diabetes, pharmacy coverage, and care navigation as separate issues.

They are not separate for the woman trying to navigate them.

She is managing symptoms, seeking answers, figuring out what is covered, comparing medication costs, and balancing work, family, caregiving, and her own health at the same time. When support is fragmented, the burden lands on her. That is what we need to change.

Where GLP-1 coverage fits

GLP-1 coverage has become one of the most difficult benefit decisions employers face.

The cost pressure is real. The demand is real. The clinical landscape is changing fast. And most plans are still evaluating GLP-1s primarily through a diabetes or weight-loss lens.

But certain GLP-1s now carry an FDA-approved cardiovascular indication for adults with established cardiovascular disease and overweight or obesity.

That creates a more specific coverage question.

This is not a case for broad GLP-1 coverage.

It is a case for understanding whether a defined cardiovascular-risk population is affected by your current benefit design, what the plan already spends, and what targeted coverage would mean for that group. Employers do not need to jump from exclusion to broad coverage. They need a clearer way to evaluate the population, the criteria, the cost, and the support needed to manage care responsibly.

The first step is the data

Employers need to know how many members match a defined cardiovascular-risk profile, what the plan already spends on GLP-1s, what targeted coverage would cost, which utilization controls make sense, and where Care Guide support or care navigation would help.

Industry averages frame the issue. They do not answer what it means for your plan. Population-specific analysis does. It moves employers from a broad coverage debate to a clearer, more informed decision.

This is bigger than one medication

The GLP-1 cardiovascular question is one piece of a larger conversation about women’s care in midlife.

Employers have a real opportunity to think differently about how benefits support women during this stage of life. That includes menopause support, heart health, prescription access, affordability, care navigation, and the data to see where gaps exist.

This is not about creating another disconnected benefit. It is about helping women get the right support at the right time and helping employers make decisions with better information.

As a nurse, I believe women should not have to piece together their own care.

As someone who works closely with employers and benefits strategy, I believe employers need practical ways to see where support is missing and act on it.

The first step is understanding the population.

Rethinking GLP-1 coverage for women’s heart health

The first step isn’t changing the benefit. It’s understanding the population.

Read the white paper

Download the PBM Reform Readiness Checklist

Download the GLP-1 Planning Checklist